A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

BACKGROUND: Renal cell carcinoma is one of the most chemoresistant cancers, and its metastatic form requires administration of targeted therapies based on angiogenesis or mTOR inhibitors. Understanding how these treatments impact the human metabolism is essential to predict the host response and adj...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Jobard, Elodie, Blanc, Ellen, Négrier, Sylvie, Escudier, Bernard, Gravis, Gwenaelle, Chevreau, Christine, Elena-Herrmann, Bénédicte, Trédan, Olivier
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2015
Schlagworte:
Translational Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4647878/
https://ncbi.nlm.nih.gov/pubmed/26372698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.322
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge